Prospectively, given the pathogenetic mechanism underlying obesity-related genes SIM1 and SEMA3-PLXNA, the therapeutic role of setmelanotide can be hypothesized, and is currently being evaluated (ClinicalTrials.gov ID: NCT04963231, NCT05093634). This evidence concerns the gene SIM1 and obesity disorder.